CSCorrine M. Stahura

Corrine M. Stahura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Corrine M. Stahura has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Urinary Proteome Profiling by Several Methods Identifies Titin as the Most-Differentiating Noninvasive Urinary Biomarker of Disease Severity in Becker Muscular Dystrophy

    by Kimchi K. Le, Emily H. Canessa, Corrine M. Stahura, Jenna Mayers, Katie A. Edwards, Marissa Barbieri, Eric P. Hoffman, Yetrib Hathout

    Background: Beckers muscular dystrophy (BMD) is a clinically heterogeneous dystrophinopathy caused by in-frame mutations in the dystrophin gene, resulting in variable disease severity. This variability limits the effectiveness of standardized functional measures for tracking progression. Circulating biomarkers, including urinary titin fragments generated during muscle injury, offer a promising non-invasive approach for assessing disease status. Methods: Mass spectrometry-based urinary proteomic profiling identified titin fragments as candidate biomarkers of muscle injury in BMD. These titin fragments were validated by two independent methods, targeted mass spectrometry and ELISA, using subsets of ambulatory BMD, non-ambulatory BMD and age matched healthy volunteers. Results: Urinary titin levels were significantly elevated by 4.56-fold and 2.32-fold in ambulatory and non-ambulatory BMD patients, respectively, compared with healthy controls. Titin levels also distinguished ambulatory from non-ambulatory BMD patients, demonstrating potential utility for monitoring disease progression and therapeutic response. Conclusions: Urinary titin fragments represent a promising non-invasive biomarker for BMD, with potential applicability to related neuromuscular disorders and clinical trials evaluating disease progression and treatment efficacy.

  • Open Access

    Urinary Proteome Profiling by Several Methods, Identifies Titin as the Most-Differentiating Noninvasive Urinary Biomarker of Disease Severity in Becker Muscular Dystrophy

    by Kimchi K. Le, Emily H. Canessa, Corrine M. Stahura, Jenna Mayers, Katie A. Edwards, Marissa Barbieri, Eric P. Hoffman, Yetrib Hathout

    Background: Becker’s muscular dystrophy (BMD) is a clinically heterogeneous dystrophinopathy caused by in-frame mutations in the dystrophin gene, resulting in variable disease severity. This variability limits the effectiveness of standardized functional measures for tracking progression. Circulating biomarkers, including urinary titin fragments generated during muscle injury, offer a promising noninvasive approach for assessing disease status. Methods: Mass spectrometry-based urinary proteomic profiling identified titin fragments as candidate biomarkers of muscle injury in BMD. Titin fragments were validated in urine samples from 50 BMD subjects (33 ambulatory, 17 non-ambulatory) and 11 age-matched healthy controls using targeted mass spectrometry and ELISA. Results: Urinary titin levels were significantly elevated by 4.75-fold and 2.47-fold in ambulatory and non-ambulatory BMD patients, respectively, compared with healthy controls. Titin levels also distinguished ambulatory from non-ambulatory BMD patients, demonstrating potential utility for monitoring disease progression and therapeutic response. Conclusions: Urinary titin fragments represent a promising noninvasive biomarker for BMD, with potential applicability to related neuromuscular disorders and clinical trials evaluating disease progression and treatment efficacy.

  • Open Access

    Unconjugated p-cresol activates macrophage macropinocytosis leading to increased LDL uptake

    by Lee D. Chaves, Sham Abyad, Amanda M. Honan, Mark A. Bryniarski, Daniel I. McSkimming, Corrine M. Stahura, Steven C. Wells, Donna M. Ruszaj, Marilyn E. Morris, Richard J. Quigg, et al.

    Patients with chronic kidney disease (CKD) and end-stage renal disease suffer from increased cardiovascular events and cardiac mortality. Prior studies have demonstrated that a portion of this enhanced risk can be attributed to the accumulation of microbiota-derived toxic metabolites, with most studies focusing on the sulfonated form of p -cresol (PCS). However, unconjugated p- cresol (uPC) itself was never assessed due to rapid and extensive first-pass metabolism that results in negligible serum concentrations of uPC. These reports thus failed to consider the host exposure to uPC prior to hepatic metabolism. In the current study, not only did we measure the effect of altering the intestinal microbiota on lipid accumulation in coronary arteries, but we also examined macrophage lipid uptake and handling pathways in response to uPC. We found that atherosclerosis-prone mice fed a high-fat diet exhibited significantly higher coronary artery lipid deposits upon receiving fecal material from CKD mice. Furthermore, treatment with uPC increased total cholesterol, triglycerides, and hepatic and aortic fatty deposits in non-CKD mice. Studies employing an in vitro macrophage model demonstrated that uPC exposure increased apoptosis whereas PCS did not. Additionally, uPC exhibited higher potency than PCS to stimulate LDL uptake and only uPC induced endocytosis- and pinocytosis-related genes. Pharmacological inhibition of varying cholesterol influx and efflux systems indicated that uPC increased macrophage LDL uptake by activating macropinocytosis. Overall, these findings indicate that uPC itself had a distinct effect on macrophage biology that might have contributed to increased cardiovascular risk in patients with CKD.


  • Technical considerations to development of serological tests for SARS-CoV-2

    by Emilie Ernst, Patricia Wolfe, Corrine Stahura, Katie A. Edwards


  • Megalin-mediated albumin endocytosis in cultured murine mesangial cells

    by Mark A. Bryniarski, Benjamin M. Yee, Lee D. Chaves, Corrine M. Stahura, Rabi Yacoub, Marilyn E. Morris